Bio-Rad Laboratories, Inc.
BIOB
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 107.80% | 141.20% | 13.20% | 124.08% | -571.33% |
| Total Depreciation and Amortization | 10.22% | 9.10% | 8.36% | 5.95% | 3.53% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -96.42% | -124.04% | -17.27% | -103.11% | 267.19% |
| Change in Net Operating Assets | 109.55% | 143.88% | 52.13% | 119.71% | -86.47% |
| Cash from Operations | -0.95% | 16.92% | 19.30% | 54.34% | 48.68% |
| Capital Expenditure | 4.13% | 4.83% | 6.22% | 3.34% | 0.85% |
| Sale of Property, Plant, and Equipment | 100.00% | 0.00% | -48.98% | -61.69% | -50.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 88.35% | 3,415.09% | 78.60% | 17.02% | -77.92% |
| Cash from Investing | -150.26% | -18.41% | -223.42% | -1,656.70% | -340.05% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -66.67% | -25.00% | 45.55% | 29.70% | 48.72% |
| Issuance of Common Stock | -17.22% | -17.71% | -19.52% | -8.75% | -8.05% |
| Repurchase of Common Stock | 19.66% | -44.20% | 27.56% | -0.44% | 32.14% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 101.67% | -- | -4,900.00% | -4,900.00% | -4,900.00% |
| Cash from Financing | 27.49% | -29.43% | 20.47% | -10.02% | 26.38% |
| Foreign Exchange rate Adjustments | -295.74% | -283.70% | 8.00% | -345.59% | -7.77% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -115.79% | -50.35% | 69.61% | -308.54% | 391.27% |